Jan 12, 2026 | Acquisition Cost Index (ACI), Biosimilar, Brand Name Drugs, Drug costs, High-value formulary, MedBen Rx, News, Patient assistance program, Pharmacogenomics, Rx Costs, Rx prices
Pharmaceutical manufacturers are planning to raise list prices on at least 350 brand-name medications in the United States beginning in 2026, up from 250 drugs last year, according to new data from health care research firm 3 Axis Advisors. These increases reflect...
Dec 15, 2025 | GLP-1s, MedBen Rx, Medicaid, Pharmacies, Weight loss, Weight loss drugs, Weight management
In recent months, a growing number of U.S. states have pulled back on covering GLP-1 medications for obesity under their Medicaid programs, even as the drugs remain broadly covered for diabetes. A recent KFF survey shows that while 16 state Medicaid programs still...
Dec 1, 2025 | Acquisition Cost Index (ACI), Benefits preservation, Biosimilar, Case Study, Cost Savings, MedBen Rx, Savings
A new MedBen Rx client realized $1.19 million in combined plan and member savings in their first year – a 45.7% reduction, surpassing the $1.05 million projected savings. Per-member-per-month (PMPM) pharmacy costs tell the story: $233 under the previous PBM vs. just...
Nov 4, 2025 | Chronic conditions, Drug costs, MedBen Rx, Mental health, Prescription drugs, Rx Costs, Rx Spending
A recent GoodRx list of the 20 most prescribed medications prompted MedBen Rx to take a closer look at how our own top prescriptions compare. Because GoodRx’s rankings largely reflect individuals who pay for medications out of pocket – rather than through...
Nov 3, 2025 | GLP-1s, MedBen Rx, Obesity, Weight loss, Weight loss drugs, Weight management
A recent International Foundation of Employee Benefit Plans survey shows that while employers are open to covering GLP-1 drugs for diabetes, they’re far more hesitant to do so for weight loss. Over half of corporate and multiemployer/public plans cover GLP-1s for...
